Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Alphamab Oncology Closes $234 Million Hong Kong IPO; Climbs 35% in First Session

publication date: Dec 12, 2019

Alphamab Oncology raised $234 million in a Hong Kong IPO and traded 35% higher from its offering price to a market cap of $1.2 billion. The company has a PD-L1 candidate that could be approved in China next year and two bispecifics -- KN046 (PD-L1/CTLA4) and KN026 (HER2) -- in Phase II tests. It has eight biologics in development. About half of the proceeds will be used to support clinical development of KN046 for various solid tumors. Alphamab Oncology was spun out from Alphamab last year. More details....

Stock Symbol: (HK: 9966)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital